Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition and application thereof

A composition and drug technology, applied in the direction of drug combination, pharmaceutical formula, plant raw materials, etc., can solve the problems of complex pathogenesis and lack of specific treatment, and achieve the effects of improving enterohepatic circulation, easy to popularize and apply, and low cost.

Inactive Publication Date: 2020-04-03
陶燃
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The pathogenesis of NAFLD is complicated, and there is still a lack of effective treatment. In recent years, the incidence of NAFLD has shown a clear upward trend, and has become the number one cause of chronic liver disease and abnormal liver function in developed countries. The prevalence of NAFLD in ordinary adults is 17%~33%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] The pharmaceutical composition in this example includes the following raw materials by weight: tiger thorn 30g, chicory 30g.

[0045] 300 obese adult patients with non-alcoholic fatty liver disease were used as research objects.

[0046] Requirements for the enrollment of research subjects: (1) The body weight of all subjects must be ≥ 70kg; (2) The person or guardian voluntarily participates in the experiment and signs an informed consent before entering the study; (3) Age 18-60 years old, male or female (except for pregnant women and nursing mothers); (4) The first diagnosis must meet the diagnostic criteria for non-alcoholic fatty liver; (5) When the patient suffers from other diseases at the same time, but does not require special clinical treatment, and does not affect the path of the first diagnosis The implementation of the process can enter the path;

[0047] Exclusion criteria for research subjects: (1) Metabolic contraindications: carnitine deficiency, carnitin...

Embodiment 2

[0061] The pharmaceutical composition in this example includes the following raw materials by weight: tiger thorn 90g, chicory 90g.

[0062] 300 obese adult patients with non-alcoholic fatty liver disease were used as the research objects. The requirements for the inclusion and exclusion of the research objects and the collection of patient data were the same as those in Example 1.

[0063] Take the above-mentioned composition and take it with water, and administer tiger thorn and chicory twice a day, 90 g of tiger thorn each time, and 90 g of chicory each time, for three consecutive months.

[0064] 300 fatty liver patients were treated with the pharmaceutical composition in this example.

[0065] Patients in each group need to come to the outpatient clinic for reexamination in the 4th week, 8th week, and every month after the start of treatment, and have a terminal examination in the 3rd month to review and record the physical indicators, biochemical indicators, and imaging ...

Embodiment 3

[0071] The pharmaceutical composition in this example includes the following raw materials by weight: tiger thorn 60g, chicory 60g.

[0072] 300 obese adult patients with non-alcoholic fatty liver disease were used as the research objects. The requirements for the inclusion and exclusion of the research objects and the collection of patient data were the same as those in Example 1.

[0073] Take the above-mentioned composition and take it with water, and administer tiger thorn and chicory twice a day, 60 g of tiger thorn each time, and 60 g of chicory each time, for three consecutive months.

[0074] 300 fatty liver patients were treated with the pharmaceutical composition in this example.

[0075] Patients in each group need to come to the outpatient clinic for reexamination in the 4th week, 8th week, and every month after the start of treatment, and have a terminal examination in the 3rd month to review and record the physical indicators, biochemical indicators, and imaging ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition and an application thereof. The pharmaceutical composition comprises the following components in parts by weight: 10-100 parts of Indian damnacanthus herb and 10-100 parts of cichorium intybus; the pharmaceutical composition containing Indian damnacanthus herb and cichorium intybus is used for treating fatty liver; the Indian damnacanthus herb and the cichorium intybus have a synergistic effect, liver and intestine circulation is obviously improved, on one hand, the Indian damnacanthus herb repairs the liver, on the other hand, the cichoriumintybus prevents enterotoxin from further damaging the liver, liver and intestine treatment is achieved, and the effect of the pharmaceutical composition is larger than the sum of the Indian damnacanthus herb effect and the cichorium intybus effect; furthermore, the pharmaceutical composition has no dependence, and is safe, reliable, low in cost and easy to popularize and apply.

Description

technical field [0001] The invention relates to the technical field of drugs for treating fatty liver, in particular to a pharmaceutical composition and its application. Background technique [0002] Non-alcoholic fatty liver, also known as non-alcoholic fatty liver disease (hereinafter referred to as NAFLD), is one of the common chronic liver diseases. If it is not treated, it can further develop into liver cirrhosis and liver cancer. The pathogenesis of NAFLD is complicated, and there is still a lack of effective treatment. In recent years, the incidence of NAFLD has shown a clear upward trend, and has become the number one cause of chronic liver disease and abnormal liver function in developed countries. The prevalence of NAFLD in ordinary adults is 17% to 33%. [0003] Therefore, need badly a kind of medicine for the treatment of fatty liver. Contents of the invention [0004] In view of this, the object of the present invention is to propose a pharmaceutical composi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/74A61P1/16A61P3/06
CPCA61K36/28A61K36/74A61P1/16A61P3/06A61K2300/00
Inventor 陶燃
Owner 陶燃
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com